Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 6/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9933084 | 0.88 | BRAF (0.38) | BRAFERAP1NPC1RAB9A | |
| SCHEMBL9967976 | 0.80 | BRAF (0.68) | BRAF | |
| SCHEMBL9932549 | 0.78 | BRAF (0.41) | BRAFNPC1RAB9AEGFRKMT2A | |
| SCHEMBL9931500 | 0.78 | BRAF (0.47) | BRAFEGFR | |
| SCHEMBL9932437 | 0.77 | BRAF (0.39) | BRAFEGFR | |
| SCHEMBL9932327 | 0.77 | BRAF (0.63) | BRAF | |
| SCHEMBL9932406 | 0.77 | BRAF (0.42) | BRAFKMT2A | |
| SCHEMBL9932914 | 0.76 | BRAF (0.49) | BRAFEGFR | |
| SCHEMBL9932270 | 0.76 | BRAF (0.38) | BRAFEGFRKMT2A | |
| SCHEMBL9932676 | 0.74 | FDPS (0.44) | BRAFNPC1RAB9AEGFRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157453-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157453-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885ERAP1 3628/4885NPC1 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.